Inovio Pharmaceuticals (INO) Corporate presentation summary

Strategic focus and platform technology

• Clinical-stage biotech developing DNA medicines for HPV-related diseases, cancer, and infectious diseases.

• Proprietary platform enables design and delivery of therapeutics and vaccines that prompt the body to produce disease-fighting tools.

• Commercial-scale manufacturing for plasmids and in-house device production established.

• $84.8M in cash and no debt as of 9/30/24; $30M raised in December public offering.

Lead program: INO-3107 for recurrent respiratory papillomatosis (RRP)

• BLA submission targeted for mid-2025 under FDA accelerated approval; Breakthrough Therapy and Orphan Drug designations.

• Phase 1/2 trial showed 81% of patients had reduced surgeries, with 28% achieving complete response after one year.

• Durability data: 95% maintained or improved response at two years; clinical benefit observed across disease severity.

• Immunology data confirm induction of HPV-specific T cells that infiltrate papilloma tissue, supporting mechanism of action.

• Device array issue addressed with design and process improvements; final confirmation expected by February 2025.

Diversified clinical pipeline and partnerships

• Eight additional clinical-stage candidates targeting HPV-related diseases, oncology, and infectious diseases.

• INO-3112 advancing to Phase 3 for HPV-related throat cancer in combination with anti-PD-1 therapy.

• VGX-3100 in Phase 2 for anal HSIL in HIV-positive and negative participants; INO-5401 for glioblastoma in partnership with Regeneron.

• INO-4201 Ebola booster progressing to Phase 2; DMAb platform in Phase 1 for anti-SARS-CoV-2.

• Multiple collaborations with industry, academia, and government agencies to advance pipeline.